Speaker Profile

Ph.D., Director (Clinical R&D), Claret Bioscience

Dr. Varsha Rao is the Director of Clinical R&D at ClaretBio. She oversees the clinical applications of the novel next-generation sequence assays and analytical pipelines developed at ClaretBio with a main focus on evaluating the utility of cell-free DNA fragmentation patterns in cancer progression and treatment response monitoring. Before joining ClaretBio, she was a Research Scientist at Stanford University School of Medicine in Prof Michael Snyder’s lab. As a part of multiple consortia such as the Integrative Personalized Omics Profiling Project, the Human Microbiome Project and the NASA Twins Study she has worked on longitudinal multiomic analyses, focusing on applying transcriptomics and liquid biopsy approaches to understand nuances of metabolic diseases, cancer, infectious disease and general health. She received her PhD in Molecular and Cellular Biology from University of Maryland Baltimore County in 2012.

Clinical Dx Showcase:
Claret Bioscience

Claret Bioscience’s mission is to improve the quality of NGS data obtained from degraded, highly fragmented, and low yield samples. Our approach aims to provide a complete picture of cfDNA molecules, enhancing the sensitivity of disease screenings, and ultimately improving treatment decisions.

cfDNA Fragmentomic Approach to Precision Oncology
We describe a new approach for cancer disease monitoring that leverages cell-free DNA fragmentation patterns - looking beyond traditional rare somatic mutation detection - with a specific focus on our novel single-stranded library preparation method, SRSLY.

 Session Abstract – PMWC 2022 Silicon Valley

The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative